

## Ready to optimize your opportunities in the Prostate Cancer market?


With the prostate cancer market set to double in value over the next ten years, staying ahead in this competitive market has never been more important.

Datamonitor Healthcare's comprehensive coverage, encompassing a ten year forecast, treatment algorithms, epidemiologic analysis, as well as marketed and pipeline drug insight, will enable you to do exactly that!



### How much will the prostate cancer market grow from 2015-2024?

Total prostate cancer drug revenues in the US, Japan and five major EU markets (France, Germany, Italy, Spain, and the UK) will increase from \$6.4bn in 2015 to \$13.5bn in 2024 at a compound annual growth rate of 8.6%




Data Supplied by Datamonitor Healthcare (December 2015)

### DID YOU KNOW?

Segmentation of prostate cancer patients into clinical states is more useful for guiding treatment than using TNM staging alone

### Distribution of prevalent prostate cancer cases:


Distribution of prevalent prostate cancer cases by clinical state according to a dynamic progression model (Solo et al., 2011\*)



\*Solo K, Mehra M, Dhawan R, Valant J, Scher HI (2011) Prevalence of prostate cancer clinical states in the United States: Estimates using a dynamic progression model. Journal of Clinical Oncology, 29(suppl 15); Abstract 4637.

### Current treatments:

Zytiga, Xtandi, and Docetaxel are the dominant pharmacological treatments of mCRPC at first line




\*This does not include androgen deprivation therapy drug options that may be prescribed concurrently with the above mCRPC drugs.

Data supplied by Datamonitor Healthcare (February 2016)

### Xtandi vs Zytiga:


Xtandi sales are expected to exceed Zytiga sales, with Xtandi remaining the most valuable brand over the forecast period



Data Supplied by Datamonitor Healthcare (December 2015)


### The launch of new products will drive market growth

Seven new drugs will launch in at least one of the forecast markets (US, Japan and five major EU markets)



Data Supplied by Datamonitor Healthcare (September 2015)

### Prevalent Cases for 2016:



Data Supplied by Datamonitor Healthcare (September 2015)